Literature DB >> 24164913

FGF-23 and cognitive performance in hemodialysis patients.

David A Drew1, Hocine Tighiouart, Tammy M Scott, Kristina V Lou, Li Fan, Kamran Shaffi, Daniel E Weiner, Mark J Sarnak.   

Abstract

Although cognitive impairment is common in hemodialysis patients, the etiology of and risk factors for its development remain unclear. Fibroblast growth factor 23 (FGF-23) levels are elevated in hemodialysis patients and are associated with increased mortality and left ventricular hypertrophy. Despite FGF-23 being found within the brain, there are no prior studies assessing whether FGF-23 levels are associated with cognitive performance. We measured FGF-23 in 263 prevalent hemodialysis patients in whom comprehensive neurocognitive testing was also performed. The cross-sectional association between patient characteristics and FGF-23 levels was assessed. Principal factor analysis was used to derive two factors from cognitive test scores, representing memory and executive function, which carried a mean of 0 and a standard deviation of 1. Multivariable linear regression adjusting for age, sex, education status, and other relevant covariates was used to explore the relationship between FGF-23 and each factor. Mean age was 63 years, 46% were women and 22% were African American. The median FGF-23 level was 3098 RU/mL. Younger age, lower prevalence of diabetes, longer dialysis vintage, and higher calcium and phosphorus were independently associated with higher FGF-23 levels. Higher FGF-23 was independently associated with a lower memory score (per doubling of FGF-23, β = -0.08 SD [95% confidence interval, CI: -0.16, -0.01]) and highest quartile vs. lowest quartile (β = -0.42 SD [-0.82, -0.02]). There was no definite association of FGF 23 with executive function when examined as a continuous variable (β = -0.03 SD [-0.10, 0.04]); however, there was a trend in the quartile analysis (β = -0.28 SD [-0.63, 0.07], P = 0.13, for 4th quartile vs. 1st quartile). FGF-23 was associated with worse performance on a composite memory score, including after adjustment for measures of mineral metabolism. High FGF-23 levels in hemodialysis patients may contribute to cognitive impairment.
© 2013 International Society for Hemodialysis.

Entities:  

Keywords:  Cognition; FGF-23; hemodialysis

Mesh:

Substances:

Year:  2013        PMID: 24164913      PMCID: PMC4443906          DOI: 10.1111/hdi.12100

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  33 in total

1.  Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients.

Authors:  V Lorenzo; M Martín; M Rufino; A Jiménez; A M Malo; E Sanchez; D Hernández; M Rodríguez; A Torres
Journal:  Am J Kidney Dis       Date:  2001-06       Impact factor: 8.860

2.  Frequency of and risk factors for poor cognitive performance in hemodialysis patients.

Authors:  Mark J Sarnak; Hocine Tighiouart; Tammy M Scott; Kristina V Lou; Eric P Sorensen; Lena M Giang; David A Drew; Kamran Shaffi; James A Strom; Ajay K Singh; Daniel E Weiner
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

3.  Prevalence and correlates of cognitive impairment in hemodialysis patients: the Frequent Hemodialysis Network trials.

Authors:  Manjula Kurella Tamura; Brett Larive; Mark L Unruh; John B Stokes; Allen Nissenson; Ravindra L Mehta; Glenn M Chertow
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-24       Impact factor: 8.237

4.  Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain.

Authors:  T Yamashita; M Yoshioka; N Itoh
Journal:  Biochem Biophys Res Commun       Date:  2000-10-22       Impact factor: 3.575

Review 5.  How fibroblast growth factor 23 works.

Authors:  Shiguang Liu; L Darryl Quarles
Journal:  J Am Soc Nephrol       Date:  2007-05-09       Impact factor: 10.121

6.  High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

Authors:  Guillaume Jean; Jean-Claude Terrat; Thierry Vanel; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2009-04-25       Impact factor: 5.992

7.  Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.

Authors:  Shiguang Liu; Rong Guo; Leigh G Simpson; Zhou-Sheng Xiao; Charles E Burnham; L Darryl Quarles
Journal:  J Biol Chem       Date:  2003-07-21       Impact factor: 5.157

8.  The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.

Authors:  Hirotaka Tanaka; Takayuki Hamano; Naohiko Fujii; Kodo Tomida; Isao Matsui; Satoshi Mikami; Yasuyuki Nagasawa; Takahito Ito; Toshiki Moriyama; Masaru Horio; Enyu Imai; Yoshitaka Isaka; Hiromi Rakugi
Journal:  Bone       Date:  2009-07-23       Impact factor: 4.398

9.  Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.

Authors:  Tobias Larsson; Ulf Nisbeth; Osten Ljunggren; Harald Jüppner; Kenneth B Jonsson
Journal:  Kidney Int       Date:  2003-12       Impact factor: 10.612

10.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

View more
  19 in total

Review 1.  Extrarenal effects of FGF23.

Authors:  Dieter Haffner; Maren Leifheit-Nestler
Journal:  Pediatr Nephrol       Date:  2016-10-04       Impact factor: 3.714

2.  Klotho and fibroblast growth factor 23 in cerebrospinal fluid in children.

Authors:  Svenja Kristin Kunert; Hans Hartmann; Dieter Haffner; Maren Leifheit-Nestler
Journal:  J Bone Miner Metab       Date:  2016-03-26       Impact factor: 2.626

3.  Phosphate Dysregulation and Neurocognitive Sequelae.

Authors:  John Acquaviva; Hosam G Abdelhady; Mohammed S Razzaque
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 4.  Phosphate in the Context of Cognitive Impairment and Other Neurological Disorders Occurrence in Chronic Kidney Disease.

Authors:  Merita Rroji; Andreja Figurek; Davide Viggiano; Giovambattista Capasso; Goce Spasovski
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

Review 5.  Kidney-brain crosstalk in the acute and chronic setting.

Authors:  Renhua Lu; Matthew C Kiernan; Anne Murray; Mitchell H Rosner; Claudio Ronco
Journal:  Nat Rev Nephrol       Date:  2015-08-18       Impact factor: 28.314

6.  Left ventricular hypertrophy and cognitive function: a systematic review.

Authors:  C Restrepo; S K Patel; V Rethnam; E Werden; J Ramchand; L Churilov; L M Burrell; A Brodtmann
Journal:  J Hum Hypertens       Date:  2018-01-12       Impact factor: 3.012

7.  Differential expression of serum biomarkers in hemodialysis patients with mild cognitive decline: A prospective single-center cohort study.

Authors:  Bin Zhu; Li-Na Jin; Jian-Qin Shen; Jin-Feng Liu; Ri-Yue Jiang; Ling Yang; Jie Zhang; Ai-Lin Luo; Li-Ying Miao; Chun Yang
Journal:  Sci Rep       Date:  2018-08-16       Impact factor: 4.379

8.  Preliminary Study of Serum Biomarkers Associated With Delirium After Major Cardiac Surgery.

Authors:  Tina B McKay; James Rhee; Katia Colon; Katherine Adelsberger; Isabella Turco; Ariel Mueller; Jason Qu; Oluwaseun Akeju
Journal:  J Cardiothorac Vasc Anesth       Date:  2021-05-12       Impact factor: 2.628

9.  25-vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: a veteran population.

Authors:  Anna J Jovanovich; Michel Chonchol; Christopher B Brady; James D Kaufman; Jessica Kendrick; Alfred K Cheung; Kristen L Jablonski
Journal:  Clin Nephrol       Date:  2014-11       Impact factor: 0.975

Review 10.  FGF23 Actions on Target Tissues-With and Without Klotho.

Authors:  Beatrice Richter; Christian Faul
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-02       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.